Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (Review)

Dalianis,Tina

doi:10.3892/ijo.2014.2355

Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (Review)

Authors:
- Tina Dalianis
View Affiliations

Affiliations: Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, Karolinska University Hospital, 171 76 Stockholm, Sweden
Published online on: March 21, 2014 https://doi.org/10.3892/ijo.2014.2355
Pages: 1799-1805
Copyright: © Dalianis . This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In 2007, the International Agency for Research against Cancer (IARC) recognized human papillomavirus (HPV), especially HPV16, besides smoking and alcohol, as a risk factor for oropharyngeal squamous cell carcinoma (OPSCC), where tonsillar and base of tongue cancer dominate. Moreover, during the past decade, in many Western countries, a sharp rise in the incidence of OPSCC, more specifically of HPV-positive OPSCC has been observed. Notably, patients with HPV-positive OPSCC, where the majority are men, particularly never-smokers have a better clinical outcome than patients with HPV-negative OPSCC and other head neck cancer (roughly 80 vs. 40% disease-free survival with conventional radiotherapy and surgery). This suggests that many patients with HPV-positive OPSCC may not require the more aggressive intensified chemo-radiotherapy given to head neck cancer patients today, and could with somewhat tapered treatment maintain excellent survival, avoiding some of the severe side effects along with intensified treatment. However, before de-intensified treatment is administered additional biomarkers are necessary in combination with HPV-positive status in order to predict and select patients that will respond favorably to therapy. In conclusion, noteworthy issues within this field with an increasing cohort of patients with HPV-positive OPSCC are better-tailored therapy and prevention. Patients with HPV-positive OPSCC, with biomarkers for good response to therapy e.g., low MHC class I, or CD44 expression or high numbers of CD8+ tumor infiltrating lymphocytes, could be included in randomized trials with less severe therapy. Furthermore, possibilities to screen for HPV-positive OPSCC and to vaccinate boys against HPV infection should be further investigated.

View Figures

View References

1.	Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV and Sidransky D: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 92:709–720. 2000. View Article : Google Scholar : PubMed/NCBI
2.	Mellin H, Friesland S, Lewensohn R, Dalianis T and Munck-Wikland E: Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer. 89:300–304. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Dahlstrand HM and Dalianis T: Presence and influence of human papillomaviruses (HPV) in tonsillar cancer. Adv Cancer Res. 93:59–89. 2005. View Article : Google Scholar : PubMed/NCBI
4.	WHO: IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. International Agency for Research on Cancer; Lyon: 2007
5.	Robinson KL and Macfarlane GJ: Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? Oral Oncol. 39:31–36. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, Dalianis T and Munck-Wikland E: Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 119:2620–2623. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G and Macpherson LM: Incidence of oral and oropharyngeal cancer in United Kingdom (1990–1999) - recent trends and regional variation. Oral Oncol. 42:586–592. 2006.PubMed/NCBI
8.	Hammarstedt L, Dahlstrand H, Lindquist D, Onelöv L, Ryott M, Luo J, Dalianis T, Ye W and Munck-Wikland E: The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol. 1279:988–992. 2007. View Article : Google Scholar
9.	Sturgis EM and Cinciripini PM: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 110:1429–1435. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Chaturvedi AK, Engels EA, Anderson WF and Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 26:612–619. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Sparén P, Ye W, Dahlstrand H, Munck-Wikland E and Dalianis T: Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 125:362–366. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Braakhuis BJ, Visser O and Leemans CR: Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol. 45:e85–e89. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Attner P, Du J, Nasman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T and Munck-Wikland E: The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer. 126:2879–2884. 2010.PubMed/NCBI
14.	Marur S, D’Souza G, Westra WH and Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 11:781–789. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Ramqvist T and Dalianis T: Oropharyngeal epidemic and human papillomavirus. Emerg Infect Dis. 16:1671–1677. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Ramqvist T and Dalianis T: An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papilloma-virus (HPV) infection and aspects of treatment and prevention. Anticancer Res. 31:1515–1519. 2011.PubMed/NCBI
17.	Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS and Gillison ML: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 29:4294–4301. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Lindquist D, Romanitan M, Hammarstedt L, Nasman A, Dahlstrand H, Lindholm J, Onelöv L, Ramqvist T, Ye W, Munck-Wikland E and Dalianis T: Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol. 1:350–355. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Attner P, Du J, Näsman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T and Munck-Wikland E: Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer. 128:2892–2897. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P and Lefebvre JL: Cancer of the oropharynx. Crit Rev Oncol Hematol. 41:107–122. 2002. View Article : Google Scholar
21.	Tommasino M: The human papillomavirus family and carcinogenesis. Semin Cancer Biol. Dec 4–2013.(Epub ahead of print). pii: S1044-579X(13)00123-5. View Article : Google Scholar
22.	Zur Hausen H: Papillomavirus infections: a major cause of human cancer. Infections Causing Human Cancer. Wiley-VCH Verlag; Weinheim: pp. 145–243. 2006, PubMed/NCBI
23.	Oguejiofor KK, Hall JS, Mani N, Douglas C, Slevin NJ, Homer J, Hall G and West CM: The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma. Clin Oncol (R Coll Radiol). 25:630–638. 2013. View Article : Google Scholar : PubMed/NCBI
24.	Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO and Dubin G: HPV PATRICIA study group: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 369:2161–2170. 2007. View Article : Google Scholar
25.	Future II Study Group: Qvadrivalent vaccine against human papillomavirus to prevent high-graded cervical lesions. N Engl J Med. 356:1915–1927. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Ramqvist T, Andreasson K and Dalianis T: Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther. 7:997–1007. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Dalianis T: Immunotherapy for polyomaviruses: opportunities and challenges. Immunotherapy. 4:617–628. 2012. View Article : Google Scholar : PubMed/NCBI
28.	Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M and Dalianis T: Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer. 102:152–158. 2002. View Article : Google Scholar : PubMed/NCBI
29.	Koskinen WJ, Chen RW, Leivo I, Mäkitie A, Bäck L, Kontio R, Suuronen R, Lindqvist C, Auvinen E, Molijn A, Quint WG, Vaheri A and Aaltonen LM: Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer. 107:401–406. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Mellin Dahlstrand H, Lindquist D, Bjornestal L, Ohlsson A, Dalianis T, Munck-Wikland E and Elmberger G: P16(INK4a) correlates to human papillomavirus presence, response to radio-therapy and clinical outcome in tonsillar carcinoma. Anticancer Res. 25:4375–4383. 2005.PubMed/NCBI
31.	Mellin H, Friesland S, Auer G, Dalianis T and Munck-Wikland E: Human papillomavirus and DNA ploidy in tonsillar cancer -correlation to prognosis. Anticancer Res. 23:2821–2828. 2003.PubMed/NCBI
32.	Dahlgren L, Mellin H, Wangsa D, Heselmeyer-Haddad K, Björnestål L, Lindholm J, Munck-Wikland E, Auer G, Ried T and Dalianis T: Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer. 107:244–249. 2003. View Article : Google Scholar
33.	Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP and Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
34.	de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ and Snijders PJ: The use of general primers GP5 and GP6 elongated at their 3’ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 76:1057–1062. 1995.
35.	Tieben LM, ter Schegget J, Minnaar RP, Bouwes Bavinck JN, Berkhout RJ, Vermeer BJ, Jebbink MF and Smits HL: Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods. 42:265–279. 1993. View Article : Google Scholar : PubMed/NCBI
36.	van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ and Snijders PJ: GP5⁺/6⁺ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 40:779–787. 2002.
37.	Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Gabriel R and Quereux C: Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer. 80:1306–1311. 1999. View Article : Google Scholar : PubMed/NCBI
38.	Gravitt PE, Peyton CL, Apple RJ and Wheeler CM: Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 36:3020–3027. 1998.
39.	Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M and Waterboer T: Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol. 44:504–512. 2006. View Article : Google Scholar : PubMed/NCBI
40.	Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR and Brakenhoff RH: A novel algorithm for reliable detection of human papillomavirus in paraffin-embedded head and neck cancer specimen. Int J Cancer. 121:2465–2472. 2007. View Article : Google Scholar : PubMed/NCBI
41.	Marklund L, Näsman A, Ramqvist T, Dalianis T, Munck-Wikland E and Hammarstedt L: Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med. 1:82–88. 2012. View Article : Google Scholar : PubMed/NCBI
42.	Anaya-Saavedra G, Ramirez-Amador V, Irigoyen-Camacho ME, Garcia-Cuellar CM, Guido-Jimenez M, Mendez-Martinez R and García-Carrancá A: High association of human papillomavirus infection with oral cancer: a case-control study. Arch Med Res. 39:189–197. 2008. View Article : Google Scholar : PubMed/NCBI
43.	D’Souza G, Agrawal Y, Halpern J, Bodison S and Gillison ML: Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 199:1263–1269. 2009.PubMed/NCBI
44.	Syrjänen S and Puranen M: Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med. 11:259–274. 2000.PubMed/NCBI
45.	Näsman A, Andersson E, Nordfors C, Grün N, Johansson H, Munck-Wikland E, Massucci G, Dalianis T and Ramqvist T: MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer. 132:72–81. 2013.PubMed/NCBI
46.	Näsman A, Andersson E, Marklund L, Tertipis N, Hammarstedt-Nordenwall L, Nyberg T, Munck-Wikland E, Masucci GV, Ramqvist T and Dalianis T: HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PloS One. 8:e77025432013.PubMed/NCBI
47.	Lindquist D, Ahrlund-Richter A, Tarján M, Tot T and Dalianis T: Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res. 32:153–161. 2012.PubMed/NCBI
48.	Näsman A, Nordfors C, Grün N, Munck-Wikland E, Ramqvist T, Marklund L, Lindquist D and Dalianis T: Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival. Cancer Med. 2:507–518. 2013.PubMed/NCBI
49.	Rietbergen MM, Martens-de Kemp SR, Bloemena E, Witte BI, Brink A, Baatenburg de Jong RJ, Leemans CR, Braakhuis BJ and Brakenhoff RH: Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur J Cancer. Dec 4–2013.(Epub ahead of print). pii: S0959-8049(13)01005-8. View Article : Google Scholar
50.	Näsman A, Romanitan M, Nordfors C, Grün N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T and Ramqvist T: Tumor infiltrating CD8⁺ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One. 7:e387112012.
51.	Nordfors C, Grün N, Tertipis N, Ahrlund-Richter A, Haeggblom L, Sivars L, Du J, Nyberg T, Marklund L, Munck-Wikland E, Näsman A, Ramqvist T and Dalianis T: CD8(+) and CD4(+) tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer. 49:2522–2530. 2013.
52.	Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, Anderson ME and Lee JH: Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg. 135:1137–1146. 2009. View Article : Google Scholar : PubMed/NCBI
53.	Lajer CB, Garnæs E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D, Skotte L, Specht L, Buchwald C and Nielsen FC: The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 106:1526–1534. 2012. View Article : Google Scholar
54.	Kreimer AR, Bhatia RK, Messeguer AL, Gonzalez P, Herrero R and Giuliano AR: Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis. 37:386–391. 2010.
55.	Rautava J and Syrjanen S: Human papillomavirus infections in the oral mucosa. J Am Dent Assoc. 142:905–914. 2011. View Article : Google Scholar : PubMed/NCBI
56.	Du J, Nordfors C, Ahrlund-Richter A, Sobkowiak M, Romanitan M, Näsman A, Andersson S, Ramqvist T and Dalianis T: Prevalence of oral human papillomavirus infection among youth, Sweden. Emerg Infect Dis. 18:1468–1471. 2012. View Article : Google Scholar : PubMed/NCBI
57.	Nordfors C, Grün N, Haeggblom L, Tertipis N, Sivars L, Mattebo M, Larsson M, Häggström-Nordin E, Tydén T, Ramqvist T and Dalianis T: Oral human papillomavirus prevalence in high school students of one municipality in Sweden. Scand J Infect Dis. 45:878–881. 2013. View Article : Google Scholar : PubMed/NCBI
58.	Steinau M, Hariri S, Gillison ML, Broutian TR, Dunne EF, Tong ZY, Markowitz LE and Unger ER: Cervical and oral HPV prevalence among females in the United States. J Infect Dis. Jan 10–2014.(Epub ahead of print).
59.	D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH and Gillison ML: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 356:1944–1956. 2007.PubMed/NCBI
60.	Fakhry C, Rosenthal BT, Clark DP and Gillison ML: Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal ‘pap-test equivalent’ in high-risk populations. Cancer Prev Res. 4:1378–1384. 2011.PubMed/NCBI
61.	Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ and Wacholder S: Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 8:e683292013.PubMed/NCBI